Skip Navigation


International Immunology Advance Access originally published online on February 7, 2007
International Immunology 2007 19(3):227-237; doi:10.1093/intimm/dxl139
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/3/227    most recent
dxl139v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ahn, J. S.
Right arrow Articles by Agrawal, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ahn, J. S.
Right arrow Articles by Agrawal, B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2007. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Dendritic cells partially abrogate the regulatory activity of CD4+CD25+ T cells present in the human peripheral blood

Justin S. Ahn*, Deepa K. Krishnadas* and Babita Agrawal

Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada T6G 2S2

Correspondence to: B. Agrawal; E-mail: bagrawal{at}ualberta.ca.

The factors that influence the functionality of human CD4+CD25+ regulatory T cells are not well understood. We sought to characterize the effects of dendritic cells (DCs) on the in vitro regulatory activity of CD4+CD25+ T cells obtained from peripheral blood of healthy human donors. Flow cytometry showed that a higher proportion of CD4+CD25+(High) T cells expressed surface glucocorticoid-induced tumor necrosis factor receptor family-related protein (GITR) and CTL-associated antigen 4 than CD4+CD25 or CD4+CD25+(Med–low) T cells. Intracellular Foxp3 was equivalently expressed on CD4+CD25+(All), CD4+CD25+(High), CD4+CD25+(Med–low) and CD4+CD25 T cell populations, irrespective of GITR and CTL-associated antigen 4 expression. CD4+CD25+ T cells were isolated and then cultured in vitro with CD4+CD25 responder T cells and stimulated with anti-CD3 antibodies, and immature dendritic cells (iDCs), mature dendritic cells (mDCs), PBMCs or PBMCs plus anti-CD28 antibodies to provide co-stimulation. In addition, secretion of the Th1 cytokine IFN-{gamma}, IL-2 and the immunoregulatory cytokines, IL-10 and transforming growth factor (TGF)-ß, were also assessed in these cultures. We found that iDCs and mDCs were capable of reversing the suppression of proliferation mediated by CD4+CD25+ regulatory T cells. However, the reversal of suppression by DCs was not dependent upon the increase of IFN-{gamma} and IL-2 production or inhibition of IL-10 and/or TGF-ß production. Therefore, DCs are able to reverse the suppressive effect of regulatory T cells independent of cytokine production. These results suggest for the first time that human DCs possess unique abilities which allow them to influence the functions of regulatory T cells in order to provide fine-tuning in the regulation of T cell responses.

Keywords: CD4+25+ T cells, dendritic cells, human T cells, regulatory T cells


* These authors contributed equally to this work.

Transmitting editor: A. Falus

Received 25 September 2006, accepted 30 November 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.